Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 1;201(9):1120–1134. doi: 10.1164/rccm.201910-1975OC

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 by the American Thoracic Society

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

PMC Copyright notice

Figure 13. — (A and B) Effects of rhIGF-1 (recombinant human insulin-like growth factor-1)/BP3 (binding peptide 3) treatment on neonatal rat pulmonary artery endothelial cell (LEC) growth (A) and tube formation (B) in vitro. As shown, rhIGF-1/BP3 enhanced LEC growth and tube formation in a dose-related fashion. (C) IGF-1 treatment also stimulates neonatal rat alveolar type 2 cell growth. (D and E) In comparison with control rats, LECs (D) and alveolar type 2 cells (E) harvested after antenatal ETX exposure had decreased basal growth, which was increased with IGF-1 treatment. Bars represent mean ± SEM. CTL = control; ETX = endotoxin; Tx = therapy.